Biopharmaceuticals

Prime Therapeutics studies: Integrated pharmacy, medical data inform effective drug therapy management for high-cost conditions

Life sciences, Health sciences, Pharmacy, Pharmaceutical sciences, Biopharmaceuticals, Biotechnology, Pharmaceutical industry, Specialty drugs in the United States
Wednesday, April 7, 2021 - 1:00pm

Recently, Prime analyzed integrated pharmacy and medical claims data for specialty drug use in autoimmune conditions the top cost drivers among all drug health care expenses.

Key Points: 
  • Recently, Prime analyzed integrated pharmacy and medical claims data for specialty drug use in autoimmune conditions the top cost drivers among all drug health care expenses.
  • With the drug therapies to treat autoimmune conditions being billed on both the medical and pharmacy benefits, a complete picture can be seen with integrated medical and pharmacy analytics.
  • In addition, these findings are essential to comprehensive medical and pharmacy drug benefit management that health plans are charged with providing for their members.
  • Though less than 1% of Prime's commercially insured members suffer from these conditions, the related drug treatments were approaching 20% of all drug spend through the medical and pharmacy benefit.

BioLife Solutions Appoints Two New Independent Board Directors

Articles, Biopharmaceuticals, Bioproduction, Board of directors
Tuesday, April 6, 2021 - 1:00pm

Mike Rice, BioLife CEO, commented, "We are very pleased to welcome Amy and Rachel as new independent directors to BioLife's board.

Key Points: 
  • Mike Rice, BioLife CEO, commented, "We are very pleased to welcome Amy and Rachel as new independent directors to BioLife's board.
  • The addition of these directors complements our existing board of directors' skills and experiences, and we are confident they will provide valuable perspectives as we continue to execute our M&A strategy, drive growth and enhance value for all BioLife shareholders."
  • Amy also serves as a member of the board of directors for the ARM Foundation for Cell and Gene Medicine.
  • BioLife Solutions is a leading supplier of class-defining cell and gene therapy bioproduction tools and services.

Avantor Named Best Bioprocessing Supplier in Single-Use Manufacturing at Asia-Pacific Bioprocessing Excellence Awards 2021

Biotechnology, Life sciences, Articles, Biopharmaceuticals, Economic taxonomy, Bioprocess, Abea, Biomanufacturing
Tuesday, April 6, 2021 - 5:29am

Singapore, Apr 6, 2021 - (ACN Newswire) - Avantor Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, was named Best Bioprocessing Supplier in Single-Use Manufacturing at the Asia-Pacific Bioprocessing Excellence Awards 2021 held recently.

Key Points: 
  • Singapore, Apr 6, 2021 - (ACN Newswire) - Avantor Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, was named Best Bioprocessing Supplier in Single-Use Manufacturing at the Asia-Pacific Bioprocessing Excellence Awards 2021 held recently.
  • Avantor was also awarded Best Company in Bioprocessing Excellence for Single-use Solutions at Biologics Manufacturing Korea 2020.
  • For information, visit avantorsciences.com and find us on:
    The Asia-Pacific Bioprocessing Excellence Awards seeks to give recognition to exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence with enhanced speed, reduced cost, and superior quality.
  • 2021 marks the fifth year of ABEA, which was first established in 2017 and backed by industry requests.

The Government of Canada makes historic investment to strengthen Canada's biomanufacturing sector

Countries, Life sciences, Articles, Biopharmaceuticals, Biomanufacturing, Biotechnology, Food industry, Pharmaceutical industry, Canada
Wednesday, March 31, 2021 - 3:05pm

Today's announcement will not only reinforce Canada's biomanufacturing capacity but also strengthen our country's pandemic preparedness.

Key Points: 
  • Today's announcement will not only reinforce Canada's biomanufacturing capacity but also strengthen our country's pandemic preparedness.
  • This once-in-a-generation investment shows our government's commitment to rebuilding Canada's domestic biomanufacturing sector, focusing on both short-term strategic solutions and a longterm vision.
  • "This major new investment in biomanufacturing is an important step forward for Canada.
  • Thus far, the Government of Canada has invested in ten firms through SIF that accelerate vaccine, therapy and biomanufacturing capacity in Canada.

G-CON Manufacturing and Just - Evotec Biologics Complete the Installation of Cleanroom PODs® for the First J.POD® Facility in North America

Life sciences, Biotechnology, Articles, Health sciences, Pharmaceutical industry, Biopharmaceuticals, Semiconductor device fabrication, Evotec, Cleanroom, Biomanufacturing, Monoclonal antibody, PODS
Tuesday, March 16, 2021 - 2:15pm

The delivery advances the completion of the first J.POD manufacturing facility in North America, a one-of-a-kind cGMP biomanufacturing facility that features small intensified bioprocessing operations housed inside G-CON cleanroom PODs.

Key Points: 
  • The delivery advances the completion of the first J.POD manufacturing facility in North America, a one-of-a-kind cGMP biomanufacturing facility that features small intensified bioprocessing operations housed inside G-CON cleanroom PODs.
  • The news comes just weeks after Evotec's announcement of Just Evotec Biologics' expanded contract with the Department of Defense for the manufacturing of anti-SARS-CoV-2 monoclonal antibodies.
  • Just Evotec Biologics has adopted our cleanroom PODs as an integral component of their manufacturing technology platform and we appreciate their trust."
  • G-CON POD cleanroom units surpass traditional cleanroom structures in scalability, mobility and the possibility of repurposing the PODs once the production process reaches its lifecycle end.

Lygos and the Agile BioFoundry Generate Largest Multi-Omics Dataset to Accelerate Machine Learning Capabilities for Engineering Strains for Producing Organic Acids

Alternative medicine, Engineering, Health, Chemicals, Plastics, Environment, Manufacturing, Biotechnology, Life sciences, Biotechnology, Articles, Economic taxonomy, Biomanufacturing, Biopharmaceuticals, Food industry, Pharmaceutical industry, Malonic acid, Omics
Monday, March 15, 2021 - 12:03pm

Together, Lygos and ABF aim to demonstrate a high-throughput engineering cycle that incorporates multi-omics analysis and machine learning with industry-leading cycle times.

Key Points: 
  • Together, Lygos and ABF aim to demonstrate a high-throughput engineering cycle that incorporates multi-omics analysis and machine learning with industry-leading cycle times.
  • The project leverages Lygos expertise in designing, building and cultivating its organic acid yeast strains, as well as its malonic acid biosynthetic pathway.
  • The Agile BioFoundrys objective is to develop and deploy technologies that enable commercially-relevant biomanufacturing, including using advanced machine learning methods in non-model microbes.
  • The Agile BioFoundry is one of nine bioenergy industry consortia funded by the U.S. Department of Energy Bioenergy Technologies Office.

BioLife Solutions to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 22, 2021

Finance, Money, Economy, Corporate finance, Stock market, Biopharmaceuticals, Bioproduction, Investor relations, Therapy, Investor
Wednesday, March 10, 2021 - 1:00pm

Management will provide an overview of the Company's financial results and a general business update.

Key Points: 
  • Management will provide an overview of the Company's financial results and a general business update.
  • To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at http://www.biolifesolutions.com/earnings .
  • A webcast replay will be available approximately two hours after the call and will be archived on http://www.biolifesolutions.com/ for 90 days.
  • BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services.

Worldwide Industry for Cell Therapy Biomanufacturing to 2025 - Key Market Trends and Challenges

Life sciences, Biotechnology, Articles, Biology, Biopharmaceuticals, Biomanufacturing, Food industry, Pharmaceutical industry, Cell therapy, Manufacturing
Tuesday, February 23, 2021 - 9:00pm

This research report presents an in-depth analysis of the global cell therapy biomanufacturing market by product type, application and region.

Key Points: 
  • This research report presents an in-depth analysis of the global cell therapy biomanufacturing market by product type, application and region.
  • The report discusses the key inhibitors to the growth of cell therapy biomanufacturing.
  • The report analyzes key companies operating in the global cell therapy biomanufacturing market.
  • In this report, the cell therapy biomanufacturing market is segmented by product type, application and region.

Global Cell Therapy Biomanufacturing Market (2020 to 2025) - Featuring Lonza Group, Merck & Novartis Among Others - ResearchAndMarkets.com

Health, Other Health, Other Science, Research, Science, Biotechnology, Life sciences, Articles, Biotechnology, Biology, Biopharmaceuticals, Biomanufacturing, Food industry, Pharmaceutical industry, Cell therapy, Manufacturing
Thursday, February 18, 2021 - 4:33pm

This research report presents an in-depth analysis of the global cell therapy biomanufacturing market by product type, application and region.

Key Points: 
  • This research report presents an in-depth analysis of the global cell therapy biomanufacturing market by product type, application and region.
  • The report discusses the key inhibitors to the growth of cell therapy biomanufacturing.
  • The report analyzes key companies operating in the global cell therapy biomanufacturing market.
  • In this report, the cell therapy biomanufacturing market is segmented by product type, application and region.

BioLife Solutions Promotes Marcus Schulz to Chief Revenue Officer

Biopharmaceuticals, Bioproduction
Tuesday, February 16, 2021 - 1:00pm

BOTHELL, Wash., Feb. 16, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS)("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced the promotion of Marcus Schulz to the position of Chief Revenue Officer.

Key Points: 
  • BOTHELL, Wash., Feb. 16, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS)("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced the promotion of Marcus Schulz to the position of Chief Revenue Officer.
  • Mike Rice, BioLife Solutions CEO, remarked, "Marcus has demonstrated stellar leadership of our sales team and indirect distribution channel to deliver outstanding results.
  • His promotion to Chief Revenue Officer recognizes his accomplishments and configures our worldwide sales team for continued growth."
  • BioLife Solutions is a leading supplier of class-defining cell and gene therapy bioproduction tools and services.